These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

960 related articles for article (PubMed ID: 31258539)

  • 1. Platelets as Mediators of Thromboinflammation in Chronic Myeloproliferative Neoplasms.
    Marin Oyarzún CP; Heller PG
    Front Immunol; 2019; 10():1373. PubMed ID: 31258539
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Platelet Toll-Like Receptors Mediate Thromboinflammatory Responses in Patients With Essential Thrombocythemia.
    Marín Oyarzún CP; Glembotsky AC; Goette NP; Lev PR; De Luca G; Baroni Pietto MC; Moiraghi B; Castro Ríos MA; Vicente A; Marta RF; Schattner M; Heller PG
    Front Immunol; 2020; 11():705. PubMed ID: 32425934
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of leukocytes in myeloproliferative neoplasm thromboinflammation.
    Liu Y; Wang Y; Huang G; Wu S; Liu X; Chen S; Luo P; Liu C; Zuo X
    J Leukoc Biol; 2024 May; 115(6):1020-1028. PubMed ID: 38527797
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanisms of platelet activation in cancer-associated thrombosis: a focus on myeloproliferative neoplasms.
    Bekendam RH; Ravid K
    Front Cell Dev Biol; 2023; 11():1207395. PubMed ID: 37457287
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and laboratory significance of defective P2Y(12) pathway function in patients with myeloproliferative neoplasms: a pilot study.
    Chang H; Shih LY; Michelson AD; Dunn P; Frelinger AL; Wang PN; Kuo MC; Lin TL; Wu JH; Tang TC
    Acta Haematol; 2013; 130(3):181-7. PubMed ID: 23751441
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thrombotic disease in the myeloproliferative neoplasms.
    Falanga A; Marchetti M
    Hematology Am Soc Hematol Educ Program; 2012; 2012():571-81. PubMed ID: 23233637
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Leukocytosis, JAK2V617F mutation, and hemostasis in myeloproliferative disorders.
    Marchetti M; Falanga A
    Pathophysiol Haemost Thromb; 2008; 36(3-4):148-59. PubMed ID: 19176988
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thromboinflammation in Myeloproliferative Neoplasms (MPN)-A Puzzle Still to Be Solved.
    Bhuria V; Baldauf CK; Schraven B; Fischer T
    Int J Mol Sci; 2022 Mar; 23(6):. PubMed ID: 35328626
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].
    Iványi JL; Marton E; Plander M
    Orv Hetil; 2011 Nov; 152(45):1795-803. PubMed ID: 22011365
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emerging Role of Neutrophils in the Thrombosis of Chronic Myeloproliferative Neoplasms.
    Ferrer-Marín F; Cuenca-Zamora EJ; Guijarro-Carrillo PJ; Teruel-Montoya R
    Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33498945
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Power of Extracellular Vesicles in Myeloproliferative Neoplasms: "Crafting" a Microenvironment That Matters.
    Catani L; Cavo M; Palandri F
    Cells; 2021 Sep; 10(9):. PubMed ID: 34571965
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thrombosis in Philadelphia negative classical myeloproliferative neoplasms: a narrative review on epidemiology, risk assessment, and pathophysiologic mechanisms.
    Ball S; Thein KZ; Maiti A; Nugent K
    J Thromb Thrombolysis; 2018 May; 45(4):516-528. PubMed ID: 29404876
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel Pathophysiological Mechanisms of Thrombosis in Myeloproliferative Neoplasms.
    Reeves BN; Beckman JD
    Curr Hematol Malig Rep; 2021 Jun; 16(3):304-313. PubMed ID: 33876389
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dkk3 levels in patients with myeloproliferative neoplasms.
    Medinger M; Muesser P; Girsberger S; Skoda R; Tzankov A; Buser A; Passweg J; Tsakiris DΑ
    Thromb Res; 2014 Feb; 133(2):218-21. PubMed ID: 24309205
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neutrophil Death in Myeloproliferative Neoplasms: Shedding More Light on Neutrophils as a Pathogenic Link to Chronic Inflammation.
    Marković D; Maslovarić I; Djikić D; Čokić VP
    Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163413
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
    Michiels JJ; Berneman Z; Schroyens W; De Raeve H
    Acta Haematol; 2015; 133(1):36-51. PubMed ID: 25116092
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Myeloproliferative Neoplasms Transcriptome Reveals Pro-Inflammatory Signature and Enrichment in Peripheral Blood Monocyte-Related Genes.
    Bassan VL; de Freitas Martins Felício R; Ribeiro Malmegrim KC; Attié de Castro F
    Cancer Invest; 2024 Aug; 42(7):605-618. PubMed ID: 38958254
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Experimental Modeling of Myeloproliferative Neoplasms.
    Lanikova L; Babosova O; Prchal JT
    Genes (Basel); 2019 Oct; 10(10):. PubMed ID: 31618985
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of JAK2 V617F mutation, spontaneous erythropoiesis and megakaryocytopoiesis, hypersensitive platelets, activated leukocytes, and endothelial cells in the etiology of thrombotic manifestations in polycythemia vera and essential thrombocythemia.
    Bellucci S; Michiels JJ
    Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):381-98. PubMed ID: 16810614
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Defining the thrombotic risk in patients with myeloproliferative neoplasms.
    Vianello F; Battisti A; Cella G; Marchetti M; Falanga A
    ScientificWorldJournal; 2011 May; 11():1131-7. PubMed ID: 21623459
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 48.